Page 150 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman
P. 150
Chapter 7
36. Recently, an RCT was published on the treatment efficacy of imiquimod in high-grade CIN (Grimm, Obstet Gynecol, 2012). 59 patients with high-grade CIN (CIN2-3) were randomized to receive imiquimod or placebo during 16 weeks. Disease regression and remission was significantly more common in patients who were treated with imiquimod than in patients treated with placebo (73% vs 39% and 47% vs 14% respectively). There was no disease progression in the imiquimod group. Side effects were acceptable for all patients.
If these results were to be confirmed in a larger trial, would you then consider using imiquimod in the treatment of high-grade CIN (CIN 2-3), for example in younger patients with a future pregnancy wish?
· Yes
· No
· Comment: ...
37. Would you consider participating in a randomized controlled trial, evaluating treatment efficacy of imiquimod in treatment of high-grade CIN?
· Yes
· Maybe
· No
· Comment in case of ‘maybe’ or ‘no’: ...
148